See more : National Capital Bancorp, Inc. (NACB) Income Statement Analysis – Financial Results
Complete financial analysis of Hikal Limited (HIKAL.BO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Hikal Limited, a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- AVT Natural Products Limited (AVTNPL.NS) Income Statement Analysis – Financial Results
- Marston’s PLC (MARZF) Income Statement Analysis – Financial Results
- MacKenzie Realty Capital, Inc. (MKZR) Income Statement Analysis – Financial Results
- Integra Essentia Limited (ESSENTIA.NS) Income Statement Analysis – Financial Results
- Orthofix Medical Inc. (OFIX) Income Statement Analysis – Financial Results
Hikal Limited (HIKAL.BO)
About Hikal Limited
Hikal Limited, together with its subsidiaries, manufactures and sells various chemical intermediates, specialty chemicals, and active pharma ingredients to pharmaceutical, animal health, biotech, crop protection, and specialty chemicals companies in India. The company operates through two segments, Pharmaceuticals and Crop Protection. The Pharmaceuticals segment produces active pharmaceutical ingredient (APIs). The Crop Protection segment manufactures pesticides and herbicides, which include diuron tech, temephos tech, thiacloprid tech, clothianidin tech, dichloroaniline, N-bromosuccinimide, prothioconazole technical, trifloxystrobin technical, and BIT. It also collaborates with other companies and offer solutions in contract research, custom synthesis, and custom manufacturing of intermediates and active ingredients. In addition, the company offers human health products, such as anti-convulsant, anti-emetic, anti-histaminic, anti-depressant, anti-psychotic, anti-lipemic, hemorheologic, anti-diabetic, anti-thrombotic, anti-hypertensive, anti-inflammation, and analgesic; animal health products, such as anti-tick, anti-parasitic, analgesic, anabolic steroids, female sex hormone, and NSAID; and specialty biocides and antimicrobial actives, as well as additives for leather, paint coatings, paper, water treatment, personal care, building materials, and textile industries. It also exports its products. The company operates in the United States, Canada, Europe Union, Japan, Latin America, and internationally. Hikal Limited was incorporated in 1988 and is headquartered in Navi Mumbai, India.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 17.69B | 20.05B | 19.26B | 17.07B | 14.62B | 15.88B | 12.99B | 10.33B | 9.08B | 8.59B | 8.28B | 6.59B | 7.07B | 5.02B | 5.39B | 5.73B | 4.79B | 4.36B |
| Cost of Revenue | 8.64B | 11.42B | 10.33B | 9.37B | 8.02B | 8.81B | 7.23B | 5.46B | 4.80B | 4.41B | 3.87B | 2.71B | 3.23B | -132.77M | 2.78B | 3.51B | 3.06B | 2.84B |
| Gross Profit | 9.05B | 8.62B | 8.93B | 7.70B | 6.61B | 7.07B | 5.76B | 4.87B | 4.28B | 4.19B | 4.40B | 3.88B | 3.83B | 5.16B | 2.61B | 2.22B | 1.73B | 1.52B |
| Gross Profit Ratio | 51.15% | 43.02% | 46.35% | 45.13% | 45.18% | 44.52% | 44.34% | 47.14% | 47.16% | 48.72% | 53.22% | 58.91% | 54.25% | 102.64% | 48.51% | 38.76% | 36.20% | 34.78% |
| Research & Development | 0.00 | 708.39M | 619.36M | 530.65M | 482.41M | 443.68M | 392.14M | 344.25M | 306.58M | 0.00 | 0.00 | 318.66M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 614.44M | 570.68M | 426.16M | 225.26M | 210.29M | 156.31M | 116.35M | 137.38M | 121.78M | 119.82M | 111.07M | 84.72M | 109.93M | 425.03M | 416.29M | 530.62M | 545.03M | 520.31M |
| Selling & Marketing | 280.74M | 294.17M | 386.89M | 301.31M | 185.57M | 208.59M | 209.06M | 166.99M | 158.25M | 177.45M | 150.34M | 98.69M | 152.18M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 895.18M | 864.85M | 813.05M | 526.57M | 395.86M | 364.90M | 325.41M | 304.37M | 280.03M | 297.27M | 261.41M | 183.41M | 262.11M | 425.03M | 416.29M | 530.62M | 545.03M | 520.31M |
| Other Expenses | 8.15B | 50.00K | 6.25M | 10.13M | 700.00K | 2.87M | 5.16M | 9.21M | 5.91M | 3.80M | 330.71M | 250.00K | 610.00K | 533.14M | 96.66M | 0.00 | 166.61M | 139.25M |
| Operating Expenses | 9.05B | 7.14B | 6.48B | 5.32B | 4.70B | 4.94B | 4.14B | 3.53B | 3.12B | 2.98B | 2.97B | 2.49B | 2.38B | 1.39B | 1.26B | 1.25B | 1.05B | 1.14B |
| Cost & Expenses | 17.69B | 18.56B | 16.81B | 14.68B | 12.71B | 13.75B | 11.37B | 8.99B | 7.92B | 7.39B | 6.84B | 5.20B | 5.61B | -132.77M | 4.03B | 4.76B | 4.11B | 3.98B |
| Interest Income | 19.58M | 19.56M | 17.56M | 26.67M | 25.24M | 19.77M | 30.46M | 25.13M | 12.45M | 11.97M | 9.74M | 11.36M | 9.48M | 0.00 | 0.00 | 0.00 | 9.97M | 20.36M |
| Interest Expense | 563.70M | 409.33M | 261.92M | 319.45M | 461.56M | 475.23M | 456.39M | 479.21M | 454.95M | 504.79M | 545.67M | 478.12M | 450.21M | 437.19M | 380.18M | 329.34M | 166.61M | 146.65M |
| Depreciation & Amortization | 1.18B | 1.09B | 956.69M | 852.45M | 824.62M | 928.79M | 855.93M | 691.41M | 672.76M | 641.90M | 550.36M | 490.74M | 453.07M | 410.75M | 358.18M | 230.36M | 277.25M | 190.28M |
| EBITDA | 2.66B | 2.60B | 3.44B | 3.28B | 2.58B | 2.93B | 2.46B | 1.98B | 1.83B | 1.84B | 2.21B | 1.30B | 1.41B | 132.77M | 1.17B | 899.63M | 976.49M | 549.95M |
| EBITDA Ratio | 15.04% | 12.71% | 17.66% | 19.01% | 18.53% | 18.50% | 18.81% | 19.86% | 18.32% | 20.34% | 25.80% | 19.48% | 23.23% | 2.64% | 21.68% | 16.65% | 20.02% | 12.84% |
| Operating Income | 32.11M | 1.49B | 2.46B | 2.29B | 1.56B | 1.91B | 1.46B | 800.24M | 531.90M | 597.52M | 981.35M | 330.49M | 728.96M | -277.98M | 810.19M | 723.70M | 681.80M | 369.32M |
| Operating Income Ratio | 0.18% | 7.44% | 12.78% | 13.44% | 10.69% | 12.02% | 11.23% | 7.75% | 5.86% | 6.96% | 11.86% | 5.01% | 10.31% | -5.53% | 15.03% | 12.63% | 14.23% | 8.48% |
| Total Other Income/Expenses | 922.94M | -5.32B | -4.73B | -3.98B | -644.76M | -639.06M | -497.94M | -2.85B | -470.98M | -473.69M | -1.16B | -1.06B | -923.97M | -461.87M | -927.42M | -329.34M | -182.61M | -194.54M |
| Income Before Tax | 955.05M | 1.05B | 2.19B | 2.06B | 1.27B | 1.49B | 1.11B | 802.65M | 531.90M | 597.52M | 981.26M | 330.69M | 511.08M | 347.14M | 430.01M | 394.36M | 499.19M | 182.18M |
| Income Before Tax Ratio | 5.40% | 5.26% | 11.35% | 12.09% | 8.66% | 9.39% | 8.59% | 7.77% | 5.86% | 6.96% | 11.86% | 5.02% | 7.23% | 6.91% | 7.98% | 6.88% | 10.42% | 4.18% |
| Income Tax Expense | 259.03M | 269.83M | 580.60M | 732.85M | 421.43M | 460.08M | 342.67M | 125.49M | 119.89M | 193.47M | 342.27M | 78.24M | 50.74M | -23.07M | -69.99M | 32.34M | 39.63M | 37.83M |
| Net Income | 696.02M | 783.90M | 1.60B | 1.33B | 844.35M | 1.03B | 772.27M | 677.16M | 412.01M | 404.05M | 638.99M | 252.45M | 460.34M | 371.71M | 502.80M | 407.76M | 474.37M | 191.07M |
| Net Income Ratio | 3.94% | 3.91% | 8.33% | 7.80% | 5.77% | 6.49% | 5.95% | 6.55% | 4.54% | 4.70% | 7.72% | 3.83% | 6.51% | 7.40% | 9.33% | 7.12% | 9.90% | 4.38% |
| EPS | 5.64 | 6.36 | 13.02 | 10.80 | 6.85 | 8.36 | 6.26 | 5.46 | 3.34 | 3.28 | 5.18 | 2.05 | 3.73 | 3.00 | 4.06 | 3.42 | 4.17 | 1.67 |
| EPS Diluted | 5.64 | 6.36 | 13.02 | 10.80 | 6.85 | 8.36 | 6.26 | 5.46 | 3.34 | 3.28 | 5.18 | 2.05 | 3.73 | 2.94 | 3.91 | 3.29 | 4.02 | 1.67 |
| Weighted Avg Shares Out | 123.40M | 123.30M | 123.30M | 123.30M | 123.30M | 123.30M | 123.30M | 123.30M | 123.30M | 123.30M | 123.30M | 123.30M | 123.30M | 123.30M | 123.30M | 123.30M | 113.10M | 113.10M |
| Weighted Avg Shares Out (Dil) | 123.30M | 123.30M | 123.30M | 123.30M | 123.30M | 123.30M | 123.30M | 123.30M | 123.30M | 123.30M | 123.30M | 123.30M | 123.30M | 123.30M | 128.73M | 123.73M | 119.28M | 123.83M |
Source: https://incomestatements.info
Category: Stock Reports